B+
Bull case
25%
Probability
Target price
$118.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
ZBH
Zimmer BiometANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$105.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$85.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+75.3
Score
AI commentary
The company source is concrete and recent: the Aug. 5 Form 8-K earnings exhibit reports the Q2 results, guidance increase, operating drivers, and product milestones [#SEC-8K-2026-08-05]. News tone is constructive, but the Aug. 7 market snapshot showed a roughly 0.7% decline from the prior close, and no reliable post-print analyst revision or target-change evidence was identified. Social and options evidence are unavailable; this remains a cautious T+3 monitoring view rather than a strong directional signal.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventQ2 2026 results and raised outlookMedium impact
Zimmer Biomet’s Exhibit 99.1 earnings release filed with its Aug. 5 Form 8-K reported Q2 sales of $2.177 billion, 4.0% organic constant-currency growth, adjusted EPS of $2.07, and $308.3 million of free cash flow. Full-year organic constant-currency revenue guidance increased to 2.25%-3.25% and adjusted EPS guidance to $8.47-$8.59 [#SEC-8K-2026-08-05].
2026-08-15catalystPost-earnings digestion after guidance raiseMedium impact
The company’s Q2 release and raised full-year outlook were constructive, but a market snapshot showed ZBH at $96.55 on Aug. 7, down 0.68%, versus the Aug. 6 RankAlpha anchor of $97.19. No reliable post-print analyst revision or target change was identified, so near-term trading may remain range-bound [#SEC-8K-2026-08-05].
2026-12-31catalystROSA Shoulder launch and innovation-cycle conversionHigh impact
The company received FDA 510(k) clearance and completed first cases for the next-generation ROSA Shoulder System, while technology, data and surgical sales grew 21.5% organically in Q2. Sustained adoption and conversion of the innovation cycle into durable growth remain a medium-term upside test [#SEC-8K-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology